The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / A Deep-Dive Discussion with the Author of a Systemic Scleroderma Study

A Deep-Dive Discussion with the Author of a Systemic Scleroderma Study

August 17, 2018 • By Elizabeth Hofheinz, MPH, MEd

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Red, shiny, tight skin on the hand due to scleroderma.

Red, shiny, tight skin on the hand due to scleroderma.
Dr P. Marazzi / Science Source

“You have systemic sclerosis,” says the physician.

You Might Also Like
  • From the Expert: New Advances in Treatment of Systemic Scleroderma
  • Low Blood Pressure Increases Risk of Death in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
  • ACR/ARHP Annual Meeting 2012: Serum Antibodies Offer Useful Clinical Insights into Systemic Sclerosis
Explore This Issue
August 2018

Other somber words patients may hear the day they learn their diagnosis include, “rare, chronic, no treatment.” But a ray of hope could soon enter those exam rooms thanks to research conducted by a team from the UK.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Rizgar A. Mageed, PhD, FRCP, FRCPath, is professor of experimental immunology at the Centre for Experimental Medicine and Rheumatology at Queen Mary University of London. His most recent study, “Association of Defective Regulation of Autoreactive Interleukin-6-Producing Transitional B Lymphocytes with Disease in Patients with Systemic Sclerosis,” appears in the March 2018 edition of Arthritis & Rheumatology.1

Dr. Mageed discusses what he’s learned with The Rheumatologist.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

B Lymphocytes

Dr. Mageed

Dr. Mageed

“Systemic sclerosis (SSc) is a disease with no cure and a high rate of mortality,” Dr. Mageed says. “One significant feature is fibrosis that emanates from an excessive deposition of proteins in the extracellular matrix of the skin and visceral organs that ultimately damage the skin, cardiovascular system and lungs. The disease is associated with autoantibodies … so in scleroderma patients, the immune system produces antibodies that don’t kill pathogens but attack self-proteins.

“The important thing about autoantibodies in patients with SSc is that some have skin involvement, others have lung involvement [and others involve] the cardiovascular system … and the type of autoantibodies seems related to the [patient’s] distinct symptoms and organ involvement,” Dr. Mageed continues. “The role of these antibodies in causing the disease is that they appear prior to the disease onset. But we know little about the origin of autoantibody-producing B lympho­cytes, [or] why they are activated. [In our study], we set out to determine the mechanisms that could contribute to the generation of disease-causing B cells, and to find out more about how B cells contribute to disease in SSc patients.

“Some clinicians have tried using biological agents that eliminate all B lymphocytes, finding that some patients benefit clinically but others do not,” he says. “This is further confirmation that B lymphocytes do play an important disease-causing role in scleroderma.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“In healthy individuals,” explains Dr. Mageed, “immune cells are well regulated, [so they] are not making autoantibodies because of immunological tolerance, the process whereby healthy individuals make lymphocytes and those that seem risky are deleted. In SSc, however, patients have B lymphocytes that recognize self-proteins and make autoantibodies.”

Checkpoints Gone Awry

Dr. Mageed says, “B lymphocytes are produced in the bone marrow and go through a lengthy maturation process. Before leaving the bone marrow, they undergo a rigorous immunological tolerance process so that nearly all B lymphocytes that can recognize self-proteins are killed off. Some B lymphocytes manage to get through, however, and thus leave the bone marrow and get into the blood. But the body has anticipated this kind of issue and has backup systems. Whatever self-reactive B lymphocytes don’t get eliminated in the bone marrow will be removed before they mature into adult B cells.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Scleroderma Tagged With: B lymphocytes, Dr. Rizgar Mageed, SSc, systemic scleroderma, Systemic sclerosisIssue: August 2018

You Might Also Like:
  • From the Expert: New Advances in Treatment of Systemic Scleroderma
  • Low Blood Pressure Increases Risk of Death in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
  • ACR/ARHP Annual Meeting 2012: Serum Antibodies Offer Useful Clinical Insights into Systemic Sclerosis
  • Studies Show Promise for Scleroderma Therapy and Prediction of Progressing Disease

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)